Home  >  News
Msc_Apr22 Advertisement
you can get e-magazine links on WhatsApp. Click here
Clinical Trials + Font Resize -

Bio-Thera begins patient dosing in Australia for BAT6021 to treat solid tumours

Guangzhou, China
Tuesday, January 25, 2022, 10:00 Hrs  [IST]

Bio-Thera Solutions, Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in phase 1 clinical study to evaluate the pharmacokinetics, safety, and preliminary anti-tumour activity of BAT6021, a monoclonal antibody with enhanced ADCC targeting TIGIT in cancer cells.

“BAT6021 is Bio-Thera’s third IO asset that has entered phase 1 study in a month.” said Dr. Shengfeng Li, CEO, Bio-Thera Solutions.  “We plan to explore combinations of BAT6021 with our other oncology assets to treat a broad range of cancers.” Dr. Shengfeng Li continued, “We are very pleased to see BAT6021 enter clinical study in Australia, as this is an important step for bringing this innovative and highly differentiated anti-TIGIT antibody to cancer patients.”

BAT6021 has demonstrated highly potent single-agent and combinatorial anti-tumour activity in in vivo pharmacology studies. The phase 1, multicenter, open-label, dose-escalation clinical trial of BAT6021 is designed to assess the safety and tolerability of BAT6021 as a single agent and in combination with BAT1308, a novel anti-PD-1 antibody in advanced solid tumour patients. Key objectives in the study include determining maximum tolerated dose and recommended phase 2 dose (RP2D), pharmacokinetics and preliminary anti-tumour activity in the monotherapy and combination therapy. Disease-specific expansion cohorts will be enrolled at the RP2D in Australia, China and other countries to further evaluate the safety and efficacy of BAT6021 in a series of malignancies.

Bio-Thera Solutions is developing several additional innovative oncology assets directed at important IO targets, including PD-1, OX40, CTLA-4, CD47, and IO bispecifics targeting synergistic targets like PD-L1/CD47.

Bio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |